Çàðåãèñòðèðîâàòüñÿ

Ïîõîæèå òåìû

  1. Ïðî ïîëèêèñòîçíî èçìåíåííûå ÿè÷íèêè.
    îò DmSS â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 4
    : 27.06.2005, 12:04
  2. èçìåíåííûå è íåèçìåíåííûå ýðèòðîöèòû
    îò èãîðü â ðàçäåëå Óðîëîã-àíäðîëîã
    Îòâåòîâ: 1
    : 09.11.2004, 17:04
  3. Êèñòîçíî èçìåíåííûå ÿè÷íèêè
    îò ULLA â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 2
    : 29.09.2004, 21:00
  4. èçìåíåííûå ýðèòðîöèòû â ìî÷å
    îò vyshelzaj â ðàçäåëå Ïåäèàòð - âñå î äåòÿõ.
    Îòâåòîâ: 12
    : 01.09.2004, 19:30
  5. èçìåíåííûå ýðèòðîöèòû â ìî÷å
    îò Ñåðãåé_Ð â ðàçäåëå Óðîëîã-àíäðîëîã
    Îòâåòîâ: 3
    : 01.09.2004, 19:30
  1. Ñåðãåé_Ð
    #1
    ×èòàòåëü Íåäóã.Ðó
    Äåâî÷êà 2,4 ãîäà ïåðåáîëåëà ÎÐÂÈ ñ òåìïåðàòóðîé 39,8 (ëå÷åíèå: íóðîôåí, ñâå÷è öåôåêîí, îöèëëîêîêöèíóì), ïîñëå â ìî÷å ïîÿâèëàñü ðåàêöèÿ íà êðîâü ++ è èçìåíåííûå ýðèòðîöèòû. Ïîÿâèëèñü ÷àñòûå ïîçûâû ê ìî÷åèñïóñêàíèþ. Ïîñòàâèëè äèàãíîç - öèñòèò (ëå÷åíèå - ìîíìóðàë è êàíåôðîí). ×àñòûå ïîçûâû ïðåêðàòèëèñü, íî ïîêàçàòåëè ìî÷è íå ìåíÿþòñÿ (ýðèòðîöèòû ïî Íå÷èïîðåíêî 2500-7500 â ðàçíûõ àíàëèçàõ). Áèîõèìèÿ (Mg, Cl, K, Ca, ìî÷åâàÿ ê-òà) â íîðìå, ïîñåâ íè÷åãî íå âûÿâèë. Êðîâü -âñå ïîê-ëè â íîðìå, ýíòåðîáèîç, ÿéöåãëèñò - îòðèöàòåëüíî. ÓÇÈ äî è ïîñëå ìî÷åèñïóñêàíèÿ ïàòîëîãèè íå âûÿâèë. Ñîîòíîøåíèå âûïèòî-âûäåëåíî â ñðåäíåì 660-510 ìë. Âðà÷è ñ äèàãíîçîì è ìåòîäàìè ëå÷åíèÿ ðàñõîäÿòñÿ. Êàêîâî Âàøå ìíåíèå? Âîçìîæíî, òðåáóåòñÿ åùå êàêîå-òî èññëåäîâàíèå? ß ïåðåæèâàþ, ÷òî çà âðåìÿ, ÷òî ÿ çàíèìàþñü ñäà÷åé àíàëèçîâ è áåãàíèåì ïî âðà÷àì, áîëåçíü ïðèîáðåòåò õðîíè÷åñêîå òå÷åíèå.

  2. Ganglion
    #2
    ×èòàòåëü Íåäóã.Ðó
    Äåâî÷êà 2,4 ãîäà ïåðåáîëåëà ÎÐÂÈ ñ òåìïåðàòóðîé 39,8 (ëå÷åíèå: íóðîôåí, ñâå÷è öåôåêîí, îöèëëîêîêöèíóì), ïîñëå â ìî÷å ïîÿâèëàñü ðåàêöèÿ íà êðîâü ++ è èçìåíåííûå ýðèòðîöèòû. Ïîÿâèëèñü ÷àñòûå ïîçûâû ê ìî÷åèñïóñêàíèþ. Ïîñòàâèëè äèàãíîç - öèñòèò (ëå÷åíèå - ìîíìóðàë è êàíåôðîí). ×àñòûå ïîçûâû ïðåêðàòèëèñü, íî ïîêàçàòåëè ìî÷è íå ìåíÿþòñÿ (ýðèòðîöèòû ïî Íå÷èïîðåíêî 2500-7500 â ðàçíûõ àíàëèçàõ). Áèîõèìèÿ (Mg, Cl, K, Ca, ìî÷åâàÿ ê-òà) â íîðìå, ïîñåâ íè÷åãî íå âûÿâèë. Êðîâü -âñå ïîê-ëè â íîðìå, ýíòåðîáèîç, ÿéöåãëèñò - îòðèöàòåëüíî. ÓÇÈ äî è ïîñëå ìî÷åèñïóñêàíèÿ ïàòîëîãèè íå âûÿâèë. Ñîîòíîøåíèå âûïèòî-âûäåëåíî â ñðåäíåì 660-510 ìë. Âðà÷è ñ äèàãíîçîì è ìåòîäàìè ëå÷åíèÿ ðàñõîäÿòñÿ. Êàêîâî Âàøå ìíåíèå? Âîçìîæíî, òðåáóåòñÿ åùå êàêîå-òî èññëåäîâàíèå? ß ïåðåæèâàþ, ÷òî çà âðåìÿ, ÷òî ÿ çàíèìàþñü ñäà÷åé àíàëèçîâ è áåãàíèåì ïî âðà÷àì, áîëåçíü ïðèîáðåòåò õðîíè÷åñêîå òå÷åíèå.



    Åñòü ëè ó Âàñ ðåçóëüòàòû áèîõèìèè êðîâè,âêëþ÷àþùèå BUN/Creatinin-àçîò ìî÷åâèíû è êðåàòèíèí?

    Ñäåëàéòå search on IgA nephropathy.Áîëüøèíñòâî ìàòåðèàëîâ íà àíãëèéñêîì ÿçûêå:



    The most common symptom of IgA nephropathy is blood in the urine. To confirm the diagnosis, a small piece of kidney tissue must be removed (biopsy) and examined. There is some concern that IgA nephropathy may actually be less rare than thought, since some people may have it but without the biopsy the disease wouldn't be detected.

    As many as 50% of people with IgA nephropathy don't develop serious disease. Studies are trying to discover how to best prevent the disease from becoming kidney failure, or even how to reverse the disease's effects. Future research could look for how the disease occurs, and how to easily test for its presence so that early treatment could be started.

    One of the most serious consequences of IgA nephropathy is that the kidney becomes so damaged that it stops working, called end-stage kidney failure or end-stage renal disease (ESRD). This will happen in about 30-40% of people with the disease. There is a lack of agreement among researchers about how to best prevent ESRD from happening in IgA nephropathy. Some of the current treatments are:



    Control of high blood pressure with diet and medication

    Steroids such as prednisone

    Drugs to suppress the immune system, such as Imuran, Cytoxan, or CellCept

    Fish oil dietary supplements

  3. Ïîëèíêà
    #3
    ×èòàòåëü Íåäóã.Ðó
    Äåâî÷êà 2,4 ãîäà ïåðåáîëåëà ÎÐÂÈ ñ òåìïåðàòóðîé 39,8 (ëå÷åíèå: íóðîôåí, ñâå÷è öåôåêîí, îöèëëîêîêöèíóì), ïîñëå â ìî÷å ïîÿâèëàñü ðåàêöèÿ íà êðîâü ++ è èçìåíåííûå ýðèòðîöèòû. Ïîÿâèëèñü ÷àñòûå ïîçûâû ê ìî÷åèñïóñêàíèþ. Ïîñòàâèëè äèàãíîç - öèñòèò (ëå÷åíèå - ìîíìóðàë è êàíåôðîí). ×àñòûå ïîçûâû ïðåêðàòèëèñü, íî ïîêàçàòåëè ìî÷è íå ìåíÿþòñÿ (ýðèòðîöèòû ïî Íå÷èïîðåíêî 2500-7500 â ðàçíûõ àíàëèçàõ). Áèîõèìèÿ (Mg, Cl, K, Ca, ìî÷åâàÿ ê-òà) â íîðìå, ïîñåâ íè÷åãî íå âûÿâèë. Êðîâü -âñå ïîê-ëè â íîðìå, ýíòåðîáèîç, ÿéöåãëèñò - îòðèöàòåëüíî. ÓÇÈ äî è ïîñëå ìî÷åèñïóñêàíèÿ ïàòîëîãèè íå âûÿâèë. Ñîîòíîøåíèå âûïèòî-âûäåëåíî â ñðåäíåì 660-510 ìë. Âðà÷è ñ äèàãíîçîì è ìåòîäàìè ëå÷åíèÿ ðàñõîäÿòñÿ. Êàêîâî Âàøå ìíåíèå? Âîçìîæíî, òðåáóåòñÿ åùå êàêîå-òî èññëåäîâàíèå? ß ïåðåæèâàþ, ÷òî çà âðåìÿ, ÷òî ÿ çàíèìàþñü ñäà÷åé àíàëèçîâ è áåãàíèåì ïî âðà÷àì, áîëåçíü ïðèîáðåòåò õðîíè÷åñêîå òå÷åíèå.

    Áåãàòü ïî âðà÷àì íå íàäî, ëó÷øå íàéòè îäíîãî òîëêîâîãî. È ýòî ïåðâåéøàÿ çàäà÷à, ò.ê. ëó÷øå ïîòðàòèòü íà ýòî âðåìÿ, ÷åì ïîòîì çàíèìàòüñÿ áåãîòíåé, âûïîëíÿÿ íå âñåãäà îïðàâäàííûå ðåêîìåíäàöèè. Åñëè èñêëþ÷åíû óðîëîãè÷åñêèå ïðè÷èíû ãåìàòóðèè ó ðåáåíêà (èíôåêöèÿ ìî÷åâûõ ïóòåé íà ïåðâîì ìåñòå, àíîìàëèè ìî÷åâîé ñèñòåìû, ðàññòðîéñòâà ìèíåðàëüíîãî îáìåíà è ìî÷åêàìåííàÿ áîëåçíü). òîãäà íàäî îáðàòèòüñÿ ê äåòñêîìó íåôðîëîãó (ïîëèêèñòîç ïî÷åê, íåôðèòû, âðîæäåííûå íàðóøåíèÿ ñâåòðûâàåìîñòè êðîâè è ò.ä.).

  4. redsys
    #4
    ×èòàòåëü Íåäóã.Ðó
    Áåãàòü ïî âðà÷àì íå íàäî, ëó÷øå íàéòè îäíîãî òîëêîâîãî.

    Òàê ìû ýòî è ïûòàåìñÿ ñäåëàòü, ïîêà ïî-ìîåìó áåçóñïåøíî. Î òîëêîâîñòè âðà÷à ìîæíî óçíàòü, ëèøü ïîñåòèâ åãî. Ïîêà íèêòî íå ïîñòàâèë îäíîçíà÷íîãî äèàãíîçà, íî âñå ïðîïèñûâàþò ëå÷åíèå. "Óãàäàé ìåëîäèþ" êàêîå-òî. Ìîæåò, êòî-òî ïîñîâåòóåò âðà÷à?

Êëèíèêà ñòîìàòîëîãèè è êîñìåòîëîãèè â Ìîñêâå

Ìåòêè ýòîé òåìû

Âàøè ïðàâà

  • Âû ìîæåòå ñîçäàâàòü íîâûå òåìû
  • Âû ìîæåòå îòâå÷àòü â òåìàõ
  • Âû íå ìîæåòå ïðèêðåïëÿòü âëîæåíèÿ
  • Âû íå ìîæåòå ðåäàêòèðîâàòü ñâîè ñîîáùåíèÿ
  •